Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020;135(21):1870-1881.

Racine-Brzostek SE, Canver MC, DeSimone RA, Zdravkova M, Lo DT, Crowley KM, et al. Thawed solvent/detergent-treated plasma demonstrates comparable clinical efficacy to thawed plasma. Transfusion. 2020;60(9):1940-1949.

Gomez-Arteaga A, Orfali N, Guarneri D, Cushing MM, Gergis U, Hsu JM, et al. Cord blood transplants supported by unrelated donor CD34 progenitor cells. Bone Marrow Transplant. 2020;55(12):2298-2307.

Medina MV, Agostino AD, Ma Q, Eroles P, Cavallin L, Chiozzini C, et al. KSHV G-protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase-2 expression mediates angiogenesis and tumorigenesis in Kaposi's sarcoma. PLoS Pathog. 2020;16(10):e1009006.

Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination and COVID19 Mortality in the USA. medRxiv. 2020.

Moscat J, Diaz-Meco MT. The interplay between PRKCI/PKCλ/ι, SQSTM1/p62, and autophagy orchestrates the oxidative metabolic response that drives liver cancer. Autophagy. 2020;16(10):1915-1917.

Lopez A, Trager MH, Magro C, Geskin LJ. Collisional variant of CD8 mycosis fungoides and indolent CD8 lymphoid proliferation. JAAD Case Rep. 2020;6(9):921-924.

Storch EK, Rogerson B, Eder AF. Trend in ABO-incompatible RBC transfusion-related fatalities reported to the FDA, 2000-2019. Transfusion. 2020;60(12):2867-2875.

Manur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, et al. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/-rearranged myeloid/lymphoid neoplasm with mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leuk Lymphoma. 2020;61(2):450-454.

Zhang T, Choi S, Zhang T, Chen Z, Chi Y, Huang S, et al. miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor. Am J Pathol. 2020;190(3):689-701.